Ublituximab for treating relapsing multiple sclerosis: A Cost Comparison Evaluation

Research output: Book/ReportCommissioned report

Original languageEnglish
PublisherNational Institute for Health and Care Excellence
Commissioning bodyNational Institute for Health and Care Excellence
Publication statusPublished - 29 Nov 2024

Cite this